|
1
|
Grunstein M and Hogness DS: Colony
hybridization: A method for the isolation of cloned DNAs that
contain a specific gene. Proc Natl Acad Sci USA. 72:3961–3965.
1975. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Taura K, Ikai I, Hatano E, Fujii H, Uyama
N and Shimahara Y: Implication of frequent local ablation therapy
for intrahepatic recurrence in prolonged survival of patients with
hepatocellular carcinoma undergoing hepatic resection: An analysis
of 610 patients over 16 years old. Ann Surg. 244:265–273. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yamamoto T, Kajino K, Kudo M, Sasaki Y,
Arakawa Y and Hino O: Determination of the clonal origin of
multiple human hepatocellular carcinomas by cloning and polymerase
chain reaction of the integrated hepatitis B virus DNA. Hepatology.
29:1446–1452. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen YJ, Yeh SH, Chen JT, Wu CC, Hsu MT,
Tsai SF, Chen PJ and Lin CH: Chromosomal changes and clonality
relationship between primary and recurrent hepatocellular
carcinoma. Gastroenterology. 119:431–440. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ochiai T, Urata Y, Yamano T, Yamagishi H
and Ashihara T: Clonal expansion in evolution of chronic hepatitis
to hepatocellular carcinoma as seen at an X-chromosome locus.
Hepatology. 31:615–621. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nomoto S, Yamashita K, Koshikawa K, Nakao
A and Sidransky D: Mitochondrial D-loop mutations as clonal markers
in multicentric hepatocellular carcinoma and plasma. Clin Cancer
Res. 8:481–487. 2002.PubMed/NCBI
|
|
7
|
Nomoto S, Kinoshita T, Kato K, Otani S,
Kasuya H, Takeda S, Kanazumi N, Sugimoto H and Nakao A:
Hypermethylation of multiple genes as clonal markers in
multicentric hepatocellular carcinoma. Br J Cancer. 97:1260–1265.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang B, Xia CY, Lau WY, Lu XY, Dong H, Yu
WL, Jin GZ, Cong WM and Wu MC: Determination of clonal origin of
recurrent hepatocellular carcinoma for personalized therapy and
outcomes evaluation: A new strategy for hepatic surgery. J Am Coll
Surg. 217:1054–1062. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ng IO, Guan XY, Poon RT, Fan ST and Lee
JM: Determination of the molecular relationship between multiple
tumour nodules in hepatocellular carcinoma differentiates
multicentric origin from intrahepatic metastasis. J Pathol.
199:345–353. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nomoto S, Hishida M, Inokawa Y, Sugimoto H
and Kodera Y: Management of hepatocellular carcinoma should
consider both tumor factors and background liver factors.
Hepatobiliary Surg Nutr. 3:82–85. 2014.PubMed/NCBI
|
|
11
|
Xie B, Zen Q, Wang X, He X, Xie Y, Zhang Z
and Li H: ACK1 promotes hepatocellular carcinoma progression via
downregulating WWOX and activating AKT signaling. Int J Oncol.
46:2057–2066. 2015.PubMed/NCBI
|
|
12
|
Liu S, Zhang W, Liu K, Ji B and Wang G:
Silencing ADAM10 inhibits the in vitro and in vivo
growth of hepatocellular carcinoma cancer cells. Mol Med Rep.
11:597–602. 2015.PubMed/NCBI
|
|
13
|
Gao L, Ge C, Fang T, Zhao F, Chen T, Yao
M, Li J and Li H: ANGPTL2 promotes tumor metastasis in
hepatocellular carcinoma. J Gastroenterol Hepatol. 30:396–404.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang HX, Jiang SS, Zhang XF, Zhou ZQ, Pan
QZ, Chen CL, Zhao JJ, Tang Y, Xia JC and Weng DS: Protein kinase
CK2α catalytic subunit is overexpressed and serves as an
unfavorable prognostic marker in primary hepatocellular carcinoma.
Oncotarget. 6:34800–34817. 2015.PubMed/NCBI
|
|
15
|
Cheng Q, Yuan F, Lu F, Zhang B, Chen T,
Chen X, Cheng Y, Li N, Ma L and Tong T: CSIG promotes
hepatocellular carcinoma proliferation by activating c-MYC
expression. Oncotarget. 6:4733–4744. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tang B, Tang F, Wang Z, Qi G, Liang X, Li
B, Yuan S, Liu J, Yu S and He S: Overexpression of CTNND1 in
hepatocellular carcinoma promotes carcinous characters through
activation of Wnt/β-catenin signaling. J Exp Clin Cancer Res.
35:822016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ruan J, Zheng H, Rong X, Rong X, Zhang J,
Fang W, Zhao P and Luo R: Over-expression of cathepsin B in
hepatocellular carcinomas predicts poor prognosis of HCC patients.
Mol Cancer. 15:172016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yi HC, Liu YL, You P, Pan JS, Zhou JY, Liu
ZJ and Zhang ZY: Overexpression of DEK gene is correlated
with poor prognosis in hepatocellular carcinoma. Mol Med Rep.
11:1318–1323. 2015.PubMed/NCBI
|
|
19
|
Liu S, Long G, Wei H, Shi L, Yang Z, Liu
D, Hu G and Qiu H: DJ-1 knockdown inhibits growth and
xenograft-induced tumor generation of human hepatocellular
carcinoma cells. Oncol Rep. 33:201–206. 2015.PubMed/NCBI
|
|
20
|
Liao W, Liu W, Liu X, Yuan Q, Ou Y, Qi Y,
Huang W, Wang Y and Huang J: Upregulation of FAM83D affects
the proliferation and invasion of hepatocellular carcinoma.
Oncotarget. 6:24132–24147. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lin CH, Lin YW, Chen YC, Liao CC, Jou YS,
Hsu MT and Chen CF: FNDC3B promotes cell migration and tumor
metastasis in hepatocellular carcinoma. Oncotarget. 7:49498–49508.
2016.PubMed/NCBI
|
|
22
|
Zhang PF, Li KS, Shen YH, Gao PT, Dong ZR,
Cai JB, Zhang C, Huang XY, Tian MX, Hu ZQ, et al: Galectin-1
induces hepatocellular carcinoma EMT and sorafenib resistance by
activating FAK/PI3K/AKT signaling. Cell Death Dis. 7:e22012016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gao K, Xu C, Jin X, Wumaier R, Ma J, Peng
J, Wang Y, Tang Y, Yu L and Zhang P: HDGF-related protein-2 (HRP-2)
acts as an oncogene to promote cell growth in hepatocellular
carcinoma. Biochem Biophys Res Commun. 458:849–855. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li Y, Yang XH, Fang SJ, Qin CF, Sun RL,
Liu ZY, Jiang BY, Wu X and Li G: HOXA7 stimulates human
hepatocellular carcinoma proliferation through cyclin E1/CDK2.
Oncol Rep. 33:990–996. 2015.PubMed/NCBI
|
|
25
|
Lv X, Li L, Lv L, Qu X, Jin S, Li K, Deng
X, Cheng L, He H and Dong L: HOXD9 promotes epithelial-mesenchymal
transition and cancer metastasis by ZEB1 regulation in
hepatocellular carcinoma. J Exp Clin Cancer Res. 34:1332015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang Y, Tao X, Jin G, Jin H, Wang N, Hu
F, Luo Q, Shu H, Zhao F, Yao M, et al: A targetable molecular
chaperone Hsp27 confers aggressiveness in hepatocellular carcinoma.
Theranostics. 6:558–570. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tang B, Qi G, Tang F, Yuan S, Wang Z,
Liang X, Li B, Yu S, Liu J, Huang Q, et al: JARID1B promotes
metastasis and epithelial-mesenchymal transition via PTEN/AKT
signaling in hepatocellular carcinoma cells. Oncotarget.
6:12723–12739. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang D, Han S, Peng R, Jiao C, Wang X,
Yang X, Yang R and Li X: Depletion of histone demethylase KDM5B
inhibits cell proliferation of hepatocellular carcinoma by
regulation of cell cycle checkpoint proteins p15 and p27. J Exp
Clin Cancer Res. 35:372016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jin H, Zhang Y, You H, Tao X, Wang C, Jin
G, Wang N, Ruan H, Gu D, Huo X, et al: Prognostic significance of
kynurenine 3-monooxygenase and effects on proliferation, migration,
and invasion of human hepatocellular carcinoma. Sci Rep.
5:104662015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang CH, Li M, Liu LL, Zhou RY, Fu J,
Zhang CZ and Yun JP: LRG1 expression indicates unfavorable clinical
outcome in hepatocellular carcinoma. Oncotarget. 6:42118–42129.
2015.PubMed/NCBI
|
|
31
|
Yao Y, Dou C, Lu Z, Zheng X and Liu Q:
MACC1 suppresses cell apoptosis in hepatocellular carcinoma by
targeting the HGF/c-MET/AKT pathway. Cell Physiol Biochem.
35:983–996. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hashimoto R, Kanda M, Takami H, Shimizu D,
Oya H, Hibino S, Okamura Y, Yamada S, Fujii T, Nakayama G, et al:
Aberrant expression of melanoma-associated antigen-D2 serves as a
prognostic indicator of hepatocellular carcinoma outcome following
curative hepatectomy. Oncol Lett. 9:1201–1206. 2015.PubMed/NCBI
|
|
33
|
Takami H, Kanda M, Oya H, Hibino S,
Sugimoto H, Suenaga M, Yamada S, Nishikawa Y, Asai M, Fujii T, et
al: Evaluation of MAGE-D4 expression in hepatocellular carcinoma in
Japanese patients. J Surg Oncol. 108:557–562. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
OuYang HY, Xu J, Luo J, Zou RH, Chen K, Le
Y, Zhang YF, Wei W, Guo RP and Shi M: MEP1A contributes to tumor
progression and predicts poor clinical outcome in human
hepatocellular carcinoma. Hepatology. 63:1227–1239. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shimizu D, Kanda M, Sugimoto H, Sueoka S,
Takami H, Ezaka K, Tanaka Y, Hashimoto R, Okamura Y, Iwata N, et
al: NRAGE promotes the malignant phenotype of hepatocellular
carcinoma. Oncol Lett. 11:1847–1854. 2016.PubMed/NCBI
|
|
36
|
Leung CO, Wong CC, Fan DN, Kai AK, Tung
EK, Xu IM, Ng IO and Lo RC: PIM1 regulates glycolysis and promotes
tumor progression in hepatocellular carcinoma. Oncotarget.
6:10880–10892. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu Y, Ye X, Zhang JB, Ouyang H, Shen Z,
Wu Y, Wang W, Wu J, Tao S, Yang X, et al: PROX1 promotes
hepatocellular carcinoma proliferation and sorafenib resistance by
enhancing β-catenin expression and nuclear translocation. Oncogene.
34:5524–5535. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wong CM, Wei L, Law CT, Ho DW, Tsang FH,
Au SL, Sze KM, Lee JM, Wong CC and Ng IO: Up-regulation of histone
methyltransferase SETDB1 by multiple mechanisms in hepatocellular
carcinoma promotes cancer metastasis. Hepatology. 63:474–487. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yang T, Song B, Zhang J, Yang GS, Zhang H,
Yu WF, Wu MC, Lu JH and Shen F: STK33 promotes hepatocellular
carcinoma through binding to c-Myc. Gut. 65:124–133. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Guo Y, Pan Q, Zhang J, Xu X, Liu X, Wang
Q, Yi R, Xie X, Yao L, Liu W, et al: Functional and clinical
evidence that TAZ is a candidate oncogene in hepatocellular
carcinoma. J Cell Biochem. 116:2465–2475. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Liu X, Liao W, Yuan Q, Ou Y and Huang J:
TTK activates Akt and promotes proliferation and migration of
hepatocellular carcinoma cells. Oncotarget. 6:34309–34320.
2015.PubMed/NCBI
|
|
42
|
Zhang XF, Pan QZ, Pan K, Weng DS, Wang QJ,
Zhao JJ, He J, Liu Q, Wang DD, Jiang SS, et al: Expression and
prognostic role of ubiquitination factor E4B in primary
hepatocellular carcinoma. Mol Carcinog. 55:64–76. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhang XF, Chao J, Pan QZ, Pan K, Weng DS,
Wang QJ, Zhao JJ, He J, Liu Q, Jiang SS, et al: Overexpression of
WWP1 promotes tumorigenesis and predicts unfavorable prognosis in
patients with hepatocellular carcinoma. Oncotarget. 6:40920–40933.
2015.PubMed/NCBI
|
|
44
|
Chai JY, Modak C, Mouazzen W, Narvaez R
and Pham J: Epithelial or mesenchymal: Where to draw the line?
Biosci Trends. 4:130–142. 2010.PubMed/NCBI
|
|
45
|
Lu Q: δ-Catenin dysregulation in cancer:
Interactions with E-cadherin and beyond. J Pathol. 222:119–123.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Schackmann RC, Tenhagen M, van de Ven RA
and Derksen PW: p120-catenin in cancer - mechanisms, models and
opportunities for intervention. J Cell Sci. 126:3515–3525. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhang L, Liu YL, Chen GX, Cui B, Wang JS,
Shi YL, Li LP and Guo XB: Heme oxygenase-1 promotes Caco-2 cell
proliferation and migration by targeting CTNND1. Chin Med J.
126:3057–3063. 2013.PubMed/NCBI
|
|
48
|
Li T, Lai Q, Wang S, Cai J, Xiao Z, Deng
D, He L, Jiao H, Ye Y, Liang L, et al: MicroRNA-224 sustains
Wnt/β-catenin signaling and promotes aggressive phenotype of
colorectal cancer. J Exp Clin Cancer Res. 35:212016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Castillo SD, Angulo B, Suarez-Gauthier A,
Melchor L, Medina PP, Sanchez-Verde L, Torres-Lanzas J, Pita G,
Benitez J and Sanchez-Cespedes M: Gene amplification of the
transcription factor DP1 and CTNND1 in human lung cancer. J
Pathol. 222:89–98. 2010.PubMed/NCBI
|
|
50
|
Noordhuis MG, Fehrmann RS, Wisman GB,
Nijhuis ER, van Zanden JJ, Moerland PD, Ver Loren van Themaat E,
Volders HH, Kok M, ten Hoor KA, et al: Involvement of the TGF-beta
and beta-catenin pathways in pelvic lymph node metastasis in
early-stage cervical cancer. Clin Cancer Res. 17:1317–1330. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Mann KM, Ward JM, Yew CC, Kovochich A,
Dawson DW, Black MA, Brett BT, Sheetz TE, Dupuy AJ, Chang DK, et
al: Australian Pancreatic Cancer Genome Initiative: Sleeping Beauty
mutagenesis reveals cooperating mutations and pathways in
pancreatic adenocarcinoma. Proc Natl Acad Sci USA. 109:5934–5941.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Xing AY, Wang YW, Su ZX, Shi DB, Wang B
and Gao P: Catenin-δ1, negatively regulated by miR-145, promotes
tumour aggressiveness in gastric cancer. J Pathol. 236:53–64. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Ito K, Stannard K, Gabutero E, Clark AM,
Neo SY, Onturk S, Blanchard H and Ralph SJ: Galectin-1 as a potent
target for cancer therapy: Role in the tumor microenvironment.
Cancer Metastasis Rev. 31:763–778. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zhang P, Zhang P, Shi B, Zhou M, Jiang H,
Zhang H, Pan X, Gao H, Sun H and Li Z: Galectin-1 overexpression
promotes progression and chemoresistance to cisplatin in epithelial
ovarian cancer. Cell Death Dis. 5:e9912014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Broder C and Becker-Pauly C: The
metalloproteases meprin α and meprin β: Unique enzymes in
inflammation, neurodegeneration, cancer and fibrosis. Biochem J.
450:253–264. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Lottaz D, Maurer CA, Hahn D, Büchler MW
and Sterchi EE: Nonpolarized secretion of human meprin alpha in
colorectal cancer generates an increased proteolytic potential in
the stroma. Cancer Res. 59:1127–1133. 1999.PubMed/NCBI
|
|
57
|
Mujica AO, Brauksiepe B, Saaler-Reinhardt
S, Reuss S and Schmidt ER: Differential expression pattern of the
novel serine/threonine kinase, STK33, in mice and men. FEBS J.
272:4884–4898. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Azoitei N, Hoffmann CM, Ellegast JM, Ball
CR, Obermayer K, Gößele U, Koch B, Faber K, Genze F, Schrader M, et
al: Targeting of KRAS mutant tumors by HSP90 inhibitors involves
degradation of STK33. J Exp Med. 209:697–711. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Scholl C, Fröhling S, Dunn IF, Schinzel
AC, Barbie DA, Kim SY, Silver SJ, Tamayo P, Wadlow RC, Ramaswamy S,
et al: Synthetic lethal interaction between oncogenic KRAS
dependency and STK33 suppression in human cancer cells.
Cell. 137:821–834. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Jelluma N, Brenkman AB, van den Broek NJ,
Cruijsen CW, van Osch MH, Lens SM, Medema RH and Kops GJ: Mps1
phosphorylates Borealin to control Aurora B activity and chromosome
alignment. Cell. 132:233–246. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Zhang L, Shi R, He C, Cheng C, Song B, Cui
H, Zhang Y, Zhao Z, Bi Y, Yang X, et al: Oncogenic
B-RafV600E abrogates the AKT/B-Raf/Mps1 interaction in
melanoma cells. Cancer Lett. 337:125–132. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Salvatore G, Nappi TC, Salerno P, Jiang Y,
Garbi C, Ugolini C, Miccoli P, Basolo F, Castellone MD, Cirafici
AM, et al: A cell proliferation and chromosomal instability
signature in anaplastic thyroid carcinoma. Cancer Res.
67:10148–10158. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Maire V, Baldeyron C, Richardson M, Tesson
B, Vincent-Salomon A, Gravier E, Marty-Prouvost B, De Koning L,
Rigaill G, Dumont A, et al: TTK/hMPS1 is an attractive therapeutic
target for triple-negative breast cancer. PLoS One. 8:e637122013.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Landi MT, Dracheva T, Rotunno M, Figueroa
JD, Liu H, Dasgupta A, Mann FE, Fukuoka J, Hames M, Bergen AW, et
al: Gene expression signature of cigarette smoking and its role in
lung adenocarcinoma development and survival. PLoS One.
3:e16512008. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Kawakami K, Brabender J, Lord RV, Groshen
S, Greenwald BD, Krasna MJ, Yin J, Fleisher AS, Abraham JM, Beer
DG, et al: Hypermethylated APC DNA in plasma and prognosis of
patients with esophageal adenocarcinoma. J Natl Cancer Inst.
92:1805–1811. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Gu D, Jin H, Jin G, Wang C, Wang N, Hu F,
Luo Q, Chu W, Yao M and Qin W: The asialoglycoprotein receptor
suppresses the metastasis of hepatocellular carcinoma via
LASS2-mediated inhibition of V-ATPase activity. Cancer Lett.
379:107–116. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Jiang CF, Wen LZ, Yin C, Xu WP, Shi B,
Zhang X and Xie WF: Apoptosis signal-regulating kinase 1 mediates
the inhibitory effect of hepatocyte nuclear factor-4α on
hepatocellular carcinoma. Oncotarget. 7:27408–27421.
2016.PubMed/NCBI
|
|
68
|
Kanda M, Sugimoto H, Nomoto S, Oya H,
Hibino S, Shimizu D, Takami H, Hashimoto R, Okamura Y, Yamada S, et
al: B-cell translocation gene 1 serves as a novel prognostic
indicator of hepatocellular carcinoma. Int J Oncol. 46:641–648.
2015.PubMed/NCBI
|
|
69
|
Kanda M, Nomoto S, Oya H, Takami H, Hibino
S, Hishida M, Suenaga M, Yamada S, Inokawa Y, Nishikawa Y, et al:
Downregulation of DENND2D by promoter hypermethylation is
associated with early recurrence of hepatocellular carcinoma. Int J
Oncol. 44:44–52. 2014.PubMed/NCBI
|
|
70
|
Hirata H, Sugimachi K, Komatsu H, Ueda M,
Masuda T, Uchi R, Sakimura S, Nambara S, Saito T, Shinden Y, et al:
Decreased expression of fructose-1,6-bisphosphatase associates with
glucose metabolism and tumor progression in hepatocellular
carcinoma. Cancer Res. 76:3265–3276. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Sun J, Li H, Huo Q, Cui M, Ge C, Zhao F,
Tian H, Chen T, Yao M and Li J: The transcription factor FOXN3
inhibits cell proliferation by downregulating E2F5 expression in
hepatocellular carcinoma cells. Oncotarget. 7:43534–43545.
2016.PubMed/NCBI
|
|
72
|
Zhang Y, Liu Y, Duan J, Yan H, Zhang J,
Zhang H, Fan Q, Luo F, Yan G, Qiao K, et al: Hippocalcin-like 1
suppresses hepatocellular carcinoma progression by promoting
p21Waf/Cip1 stabilization by activating the ERK1/2-MAPK
pathway. Hepatology. 63:880–897. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Wu BH, Chen H, Cai CM, Fang JZ, Wu CC,
Huang LY, Wang L and Han ZG: Epigenetic silencing of JMJD5
promotes the proliferation of hepatocellular carcinoma cells by
down-regulating the transcription of CDKN1A 686. Oncotarget.
7:6847–6863. 2016.PubMed/NCBI
|
|
74
|
Tanaka Y, Kanda M, Sugimoto H, Shimizu D,
Sueoka S, Takami H, Ezaka K, Hashimoto R, Okamura Y, Iwata N, et
al: Translational implication of Kallmann syndrome-1 gene
expression in hepatocellular carcinoma. Int J Oncol. 46:2546–2554.
2015.PubMed/NCBI
|
|
75
|
Zhuo H, Tang J, Lin Z, Jiang R, Zhang X,
Ji J, Wang P and Sun B: The aberrant expression of MEG3 regulated
by UHRF1 predicts the prognosis of hepatocellular carcinoma. Mol
Carcinog. 55:209–219. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Li A, Yan Q, Zhao X, Zhong J, Yang H, Feng
Z, Du Y, Wang Y, Wang Z, Wang H, et al: Decreased expression of
PBLD correlates with poor prognosis and functions as a tumor
suppressor in human hepatocellular carcinoma. Oncotarget.
7:524–537. 2016.PubMed/NCBI
|
|
77
|
Ding X, Cheng X, Gong M, Chen X, Yin F and
Lai K: Hypermethylation and expression silencing of PDCD4
gene in hepatocellular carcinoma: A consort study. Medicine.
95:e27292016. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Kanda M, Sugimoto H, Nomoto S, Oya H,
Shimizu D, Takami H, Hashimoto R, Sonohara F, Okamura Y, Yamada S,
et al: Clinical utility of PDSS2 expression to stratify
patients at risk for recurrence of hepatocellular carcinoma. Int J
Oncol. 45:2005–2012. 2014.PubMed/NCBI
|
|
79
|
Richter AM, Walesch SK, Würl P, Taubert H
and Dammann RH: The tumor suppressor RASSF10 is upregulated upon
contact inhibition and frequently epigenetically silenced in
cancer. Oncogenesis. 1:e182012. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Liu XR, Cai CX, Luo LM, Zheng WL, Shi R,
Zeng J, Xu YQ, Wei M and Ma WL: Decreased expression of Sushi
Domain Containing 2 correlates to progressive features in patients
with hepatocellular carcinoma. Cancer Cell Int. 16:152016.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Liu X, Zhou J, Zhou N, Zhu J, Feng Y and
Miao X: SYNJ2BP inhibits tumor growth and metastasis by activating
DLL4 pathway in hepatocellular carcinoma. J Exp Clin Cancer Res.
35:1152016. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Zhang X, Lv L, Ouyang X, Zhang S, Fang J,
Cai L and Li D: Association of TIP30 expression and prognosis of
hepatocellular carcinoma in patients with HBV infection. Cancer
Med. 5:2180–2189. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Wang Y, Chen CL, Pan QZ, Wu YY, Zhao JJ,
Jiang SS, Chao J, Zhang XF, Zhang HX, Zhou ZQ, et al: Decreased
TPD52 expression is associated with poor prognosis in primary
hepatocellular carcinoma. Oncotarget. 7:6323–6334. 2016.PubMed/NCBI
|
|
84
|
Shimizu D, Kanda M, Nomoto S, Oya H,
Takami H, Hibino S, Suenaga M, Inokawa Y, Hishida M, Takano N, et
al: Identification of intragenic methylation in the TUSC1 gene as a
novel prognostic marker of hepatocellular carcinoma. Oncol Rep.
31:1305–1313. 2014.PubMed/NCBI
|
|
85
|
Wu D, Liu G, Liu Y, Saiyin H, Wang C, Wei
Z, Zen W, Liu D, Chen Q, Zhao Z, et al: Zinc finger protein 191
inhibits hepatocellular carcinoma metastasis through discs large
1-mediated yes-associated protein inactivation. Hepatology.
64:1148–1162. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Tsukada Y, Fang J, Erdjument-Bromage H,
Warren ME, Borchers CH, Tempst P and Zhang Y: Histone demethylation
by a family of JmjC domain-containing proteins. Nature.
439:811–816. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Zhang R, Huang Q and Li Y, Song Y and Li
Y: JMJD5 is a potential oncogene for colon carcinogenesis. Int J
Clin Exp Pathol. 8:6482–6489. 2015.PubMed/NCBI
|
|
88
|
Zhao Z, Sun C, Li F, Han J, Li X and Song
Z: Overexpression of histone demethylase JMJD5 promotes metastasis
and indicates a poor prognosis in breast cancer. Int J Clin Exp
Pathol. 8:10325–10334. 2015.PubMed/NCBI
|
|
89
|
Huang X, Zhang S, Qi H, Wang Z, Chen HW,
Shao J and Shen J: JMJD5 interacts with p53 and negatively
regulates p53 function in control of cell cycle and proliferation.
Biochim Biophys Acta. 1853:2286–2295. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Soussi-Yanicostas N, de Castro F, Julliard
AK, Perfettini I, Chédotal A and Petit C: Anosmin-1, defective in
the X-linked form of Kallmann syndrome, promotes axonal branch
formation from olfactory bulb output neurons. Cell. 109:217–228.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
González-Martínez D, Kim SH, Hu Y, Guimond
S, Schofield J, Winyard P, Vannelli GB, Turnbull J and Bouloux PM:
Anosmin-1 modulates fibroblast growth factor receptor 1 signaling
in human gonadotropin-releasing hormone olfactory neuroblasts
through a heparan sulfate-dependent mechanism. J Neurosci.
24:10384–10392. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Jian B, Nagineni CN, Meleth S, Grizzle W,
Bland K, Chaudry I and Raju R: Anosmin-1 involved in neuronal cell
migration is hypoxia inducible and cancer regulated. Cell Cycle.
8:3770–3776. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Choy CT, Kim H, Lee JY, Williams DM,
Palethorpe D, Fellows G, Wright AJ, Laing K, Bridges LR, Howe FA,
et al: Anosmin-1 contributes to brain tumor malignancy through
integrin signal pathways. Endocr Relat Cancer. 21:85–99. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Kang YK, Hong SW, Lee H and Kim WH:
Prognostic implications of ezrin expression in human hepatocellular
carcinoma. Mol Carcinog. 49:798–804. 2010.PubMed/NCBI
|
|
95
|
Wang F, Feng Y, Li P, Wang K, Feng L, Liu
YF, Huang H, Guo YB, Mao QS and Xue WJ: RASSF10 is an
epigenetically inactivated tumor suppressor and independent
prognostic factor in hepatocellular carcinoma. Oncotarget.
7:4279–4297. 2016.PubMed/NCBI
|
|
96
|
Matsuzaki T, Hanai S, Kishi H, Liu Z, Bao
Y, Kikuchi A, Tsuchida K and Sugino H: Regulation of endocytosis of
activin type II receptors by a novel PDZ protein through
Ral/Ral-binding protein 1-dependent pathway. J Biol Chem.
277:19008–19018. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Adam MG, Berger C, Feldner A, Yang WJ,
Wüstehube-Lausch J, Herberich SE, Pinder M, Gesierich S, Hammes HP,
Augustin HG, et al: Synaptojanin-2 binding protein stabilizes the
Notch ligands DLL1 and DLL4 and inhibits sprouting angiogenesis.
Circ Res. 113:1206–1218. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Wang J, Sullenger BA and Rich JN: Notch
signaling in cancer stem cells. Adv Exp Med Biol. 727:174–185.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Brito GC, Fachel AA, Vettore AL, Vignal
GM, Gimba ER, Campos FS, Barcinski MA, Verjovski-Almeida S and Reis
EM: Identification of protein-coding and intronic noncoding RNAs
down-regulated in clear cell renal carcinoma. Mol Carcinog.
47:757–767. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Okamura Y, Nomoto S, Kanda M, Hayashi M,
Nishikawa Y, Fujii T, Sugimoto H, Takeda S and Nakao A: Reduced
expression of reelin (RELN) gene is associated with high
recurrence rate of hepatocellular carcinoma. Ann Surg Oncol.
18:572–579. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Kanda M, Nomoto S, Okamura Y, Nishikawa Y,
Sugimoto H, Kanazumi N, Takeda S and Nakao A: Detection of
metallothionein 1G as a methylated tumor suppressor gene in human
hepatocellular carcinoma using a novel method of double combination
array analysis. Int J Oncol. 35:477–483. 2009.PubMed/NCBI
|
|
102
|
Nomoto S, Kanda M, Okamura Y, Nishikawa Y,
Qiyong L, Fujii T, Sugimoto H, Takeda S and Nakao A: Epidermal
growth factor-containing fibulin-like extracellular matrix protein
1, EFEMP1, a novel tumor-suppressor gene detected in
hepatocellular carcinoma using double combination array analysis.
Ann Surg Oncol. 17:923–932. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Okamura Y, Nomoto S, Kanda M, Li Q,
Nishikawa Y, Sugimoto H, Kanazumi N, Takeda S and Nakao A: Leukemia
inhibitory factor receptor (LIFR) is detected as a novel suppressor
gene of hepatocellular carcinoma using double-combination array.
Cancer Lett. 289:170–177. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Kanda M, Nomoto S, Okamura Y, Hayashi M,
Hishida M, Fujii T, Nishikawa Y, Sugimoto H, Takeda S and Nakao A:
Promoter hypermethylation of fibulin 1 gene is associated with
tumor progression in hepatocellular carcinoma. Mol Carcinog.
50:571–579. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Hayashi M, Nomoto S, Kanda M, Okamura Y,
Nishikawa Y, Yamada S, Fujii T, Sugimoto H, Takeda S and Kodera Y:
Identification of the A kinase anchor protein 12 (AKAP12)
gene as a candidate tumor suppressor of hepatocellular carcinoma. J
Surg Oncol. 105:381–386. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Okamura Y, Nomoto S, Hayashi M, Hishida M,
Nishikawa Y, Yamada S, Fujii T, Sugimoto H, Takeda S, Kodera Y, et
al: Identification of the bleomycin hydrolase gene as a methylated
tumor suppressor gene in hepatocellular carcinoma using a novel
triple-combination array method. Cancer Lett. 312:150–157. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Hishida M, Nomoto S, Inokawa Y, Hayashi M,
Kanda M, Okamura Y, Nishikawa Y, Tanaka C, Kobayashi D, Yamada S,
et al: Estrogen receptor 1 gene as a tumor suppressor gene in
hepatocellular carcinoma detected by triple-combination array
analysis. Int J Oncol. 43:88–94. 2013.PubMed/NCBI
|
|
108
|
Inokawa Y, Nomoto S, Hishida M, Hayashi M,
Kanda M, Nishikawa Y, Takeda S, Fujiwara M, Koike M, Sugimoto H, et
al: Dynamin 3: A new candidate tumor suppressor gene in
hepatocellular carcinoma detected by triple combination array
analysis. Onco Targets Ther. 6:1417–1424. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Inokawa Y, Nomoto S, Hishida M, Hayashi M,
Kanda M, Nishikawa Y, Takeda S, Sugimoto H, Fujii T, Yamada S, et
al: Detection of doublecortin domain-containing 2 (DCDC2), a
new candidate tumor suppressor gene of hepatocellular carcinoma, by
triple combination array analysis. J Exp Clin Cancer Res.
32:652013. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Hayashi M, Nomoto S, Hishida M, Inokawa Y,
Kanda M, Okamura Y, Nishikawa Y, Tanaka C, Kobayashi D, Yamada S,
et al: Identification of the collagen type 1 α 1 gene
(COL1A1) as a candidate survival-related factor associated
with hepatocellular carcinoma. BMC Cancer. 14:1082014. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Hishida M, Inokawa Y, Takano N, Nishikawa
Y, Iwata N, Kanda M, Tanaka C, Kobayashi D, Yamada S, Nakayama G,
et al: Protein tyrosine kinase 7: A hepatocellular
carcinoma-related gene detected by triple-combination array. J Surg
Res. 195:444–453. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Takano N, Hishida M, Inokawa Y, Hayashi M,
Kanda M, Nishikawa Y, Iwata N, Kobayashi D, Tanaka C, Yamada S, et
al: CCNJ detected by triple combination array analysis as a
tumor-related gene of hepatocellular carcinoma. Int J Oncol.
46:1963–1970. 2015.PubMed/NCBI
|
|
113
|
Higuchi T, Todaka H, Sugiyama Y, Ono M,
Tamaki N, Hatano E, Takezaki Y, Hanazaki K, Miwa T, Lai S, et al:
Suppression of microRNA-7 (miR-7) biogenesis by nuclear factor
90-nuclear factor 45 complex (NF90-NF45) controls cell
proliferation in hepatocellular carcinoma. J Biol Chem.
291:21074–21084. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
You Y, Tan JX, Dai HS, Chen HW, Xu XJ,
Yang AG, Zhang YJ, Bai LH and Bie P: MiRNA-22 inhibits oncogene
galectin-1 in hepatocellular carcinoma. Oncotarget. 7:57099–57116.
2016.PubMed/NCBI
|
|
115
|
Wang Y, Sun B, Zhao X, Zhao N, Sun R, Zhu
D, Zhang Y, Li Y, Gu Q, Dong X, et al: Twist1-related miR-26b-5p
suppresses epithelial-mesenchymal transition, migration and
invasion by targeting SMAD1 in hepatocellular carcinoma.
Oncotarget. 7:24383–24401. 2016.PubMed/NCBI
|
|
116
|
Liu Z, Wang J, Mao Y, Zou B and Fan X:
MicroRNA-101 suppresses migration and invasion via targeting
vascular endothelial growth factor-C in hepatocellular carcinoma
cells. Oncol Lett. 11:433–438. 2016.PubMed/NCBI
|
|
117
|
Yen CS, Su ZR, Lee YP, Liu IT and Yen CJ:
miR-106b promotes cancer progression in hepatitis B
virus-associated hepatocellular carcinoma. World J Gastroenterol.
22:5183–5192. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Huan L, Bao C, Chen D, Li Y, Lian J, Ding
J, Huang S, Liang L and He X: MicroRNA-127-5p targets the
biliverdin reductase B/nuclear factor-κB pathway to suppress cell
growth in hepatocellular carcinoma cells. Cancer Sci. 107:258–266.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Tian Z, Jiang H, Liu Y, Huang Y, Xiong X,
Wu H and Dai X: MicroRNA-133b inhibits hepatocellular carcinoma
cell progression by targeting Sirt1. Exp Cell Res. 343:135–147.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Zeng YB, Liang XH, Zhang GX, Jiang N,
Zhang T, Huang JY, Zhang L and Zeng XC: miRNA-135a promotes
hepatocellular carcinoma cell migration and invasion by targeting
forkhead box O1. Cancer Cell Int. 16:632016. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Sakabe T, Azumi J, Umekita Y, Toriguchi K,
Hatano E, Hirooka Y and Shiota G: Prognostic relevance of miR-137
in patients with hepatocellular carcinoma. Liver Int. 37:271–279.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Yu M, Lin Y, Zhou Y, Jin H, Hou B, Wu Z,
Li Z, Jian Z and Sun J: MiR-144 suppresses cell proliferation,
migration, and invasion in hepatocellular carcinoma by targeting
SMAD4. Onco Targets Ther. 9:4705–4714. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Tang B, Lei B, Qi G, Liang X, Tang F, Yuan
S, Wang Z, Yu S and He S: MicroRNA-155-3p promotes hepatocellular
carcinoma formation by suppressing FBXW7 expression. J Exp Clin
Cancer Res. 35:932016. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Ruan T, He X, Yu J and Hang Z:
MicroRNA-186 targets Yes-associated protein 1 to inhibit Hippo
signaling and tumorigenesis in hepatocellular carcinoma. Oncol
Lett. 11:2941–2945. 2016.PubMed/NCBI
|
|
125
|
Lian J, Jing Y, Dong Q, Huan L, Chen D,
Bao C, Wang Q, Zhao F, Li J, Yao M, et al: miR-192, a prognostic
indicator, targets the SLC39A6/SNAIL pathway to reduce tumor
metastasis in human hepatocellular carcinoma. Oncotarget.
7:2672–2683. 2016.PubMed/NCBI
|
|
126
|
Deng B, Qu L, Li J, Fang J, Yang S, Cao Z,
Mei Z and Sun X: MiRNA-211 suppresses cell proliferation, migration
and invasion by targeting SPARC in human hepatocellular carcinoma.
Sci Rep. 6:266792016. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Yu G, Wang J, Xu K and Dong J: Dynamic
regulation of uncoupling protein 2 expression by microRNA-214 in
hepatocellular carcinoma. Biosci Rep. 36:362016. View Article : Google Scholar
|
|
128
|
Okajima W, Komatsu S, Ichikawa D, Miyamae
M, Kawaguchi T, Hirajima S, Ohashi T, Imamura T, Kiuchi J, Arita T,
et al: Circulating microRNA profiles in plasma: Identification of
miR-224 as a novel diagnostic biomarker in hepatocellular carcinoma
independent of hepatic function. Oncotarget. 7:53820–53836.
2016.PubMed/NCBI
|
|
129
|
Meng X, Lu P and Fan Q: miR-367 promotes
proliferation and invasion of hepatocellular carcinoma cells by
negatively regulating PTEN. Biochem Biophys Res Commun.
470:187–191. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Chen JS, Li HS, Huang JQ, Dong SH, Huang
ZJ, Yi W, Zhan GF, Feng JT, Sun JC and Huang XH: MicroRNA-379-5p
inhibits tumor invasion and metastasis by targeting FAK/AKT
signaling in hepatocellular carcinoma. Cancer Lett. 375:73–83.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Liu S, Liu K, Zhang W, Wang Y, Jin Z, Jia
B and Liu Y: miR-449a inhibits proliferation and invasion by
regulating ADAM10 in hepatocellular carcinoma. Am J Transl Res.
8:2609–2619. 2016.PubMed/NCBI
|
|
132
|
Zhang L, Yu Z, Xian Y and Lin X:
microRNA-497 inhibits cell proliferation and induces apoptosis by
targeting YAP1 in human hepatocellular carcinoma. FEBS Open Bio.
6:155–164. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Jin H, Yu M, Lin Y, Hou B, Wu Z, Li Z and
Sun J: MiR-502-3P suppresses cell proliferation, migration, and
invasion in hepatocellular carcinoma by targeting SET. Onco Targets
The. 9:3281–3289. 2016.
|
|
134
|
Xiao Y, Tian Q, He J, Huang M, Yang C and
Gong L: MiR-503 inhibits hepatocellular carcinoma cell growth via
inhibition of insulin-like growth factor 1 receptor. Onco Targets
Ther. 9:3535–3544. 2016.PubMed/NCBI
|
|
135
|
Tu K, Liu Z, Yao B, Han S and Yang W:
MicroRNA-519a promotes tumor growth by targeting PTEN/PI3K/AKT
signaling in hepatocellular carcinoma. Int J Oncol. 48:965–974.
2016.PubMed/NCBI
|
|
136
|
Wang W, Zhang H, Wang L, Zhang S and Tang
M: miR-613 inhibits the growth and invasiveness of human
hepatocellular carcinoma via targeting DCLK1. Biochem Biophys Res
Commun. 473:987–992. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Wu G, Zheng K, Xia S, Wang Y, Meng X, Qin
X and Cheng Y: MicroRNA-655-3p functions as a tumor suppressor by
regulating ADAM10 and β-catenin pathway in hepatocellular
carcinoma. J Exp Clin Cancer Res. 35:892016. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Zhou X, Zhang L, Zheng B, Yan Y, Zhang Y,
Xie H, Zhou L, Zheng S and Wang W: MicroRNA-761 is upregulated in
hepatocellular carcinoma and regulates tumorigenesis by targeting
Mitofusin-2. Cancer Sci. 107:424–432. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Tan G, Wu L, Tan J, Zhang B, Tai WC, Xiong
S, Chen W, Yang J and Li H: MiR-1180 promotes apoptotic resistance
to human hepatocellular carcinoma via activation of NF-κB signaling
pathway. Sci Rep. 6:223282016. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Yang J, Zhou F, Xu T, Deng H, Ge YY, Zhang
C, Li J and Zhuang SM: Analysis of sequence variations in 59
microRNAs in hepatocellular carcinomas. Mutat Res. 638:205–209.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Ge Y, Yan X, Jin Y, Yang X, Yu X, Zhou L,
Han S, Yuan Q and Yang M: MiRNA-192 [corrected] and miRNA-204
directly suppress lncRNA HOTTIP and interrupt GLS1-mediated
glutaminolysis in hepatocellular carcinoma. PLoS Genet.
11:e10057262015. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Cai C, Ashktorab H, Pang X, Zhao Y, Sha W,
Liu Y and Gu X: MicroRNA-211 expression promotes colorectal cancer
cell growth in vitro and in vivo by targeting tumor suppressor
CHD5. PLoS One. 7:e297502012. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Chen YF, Yang CC, Kao SY, Liu CJ, Lin SC
and Chang KW: MicroRNA-211 enhances the oncogenicity of
carcinogen-induced oral carcinoma by repressing TCF12 and
increasing antioxidant activity. Cancer Res. 76:4872–4886. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Lee H, Lee S, Bae H, Kang HS and Kim SJ:
Genome-wide identification of target genes for miR-204 and miR-211
identifies their proliferation stimulatory role in breast cancer
cells. Sci Rep. 6:252872016. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Ye L, Wang H and Liu B: miR-211 promotes
non-small cell lung cancer proliferation by targeting SRCIN1.
Tumour Biol. 37:1151–1157. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Asuthkar S, Velpula KK, Chetty C, Gorantla
B and Rao JS: Epigenetic regulation of miRNA-211 by MMP-9 governs
glioma cell apoptosis, chemosensitivity and radiosensitivity.
Oncotarget. 3:1439–1454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Levy C, Khaled M, Iliopoulos D, Janas MM,
Schubert S, Pinner S, Chen PH, Li S, Fletcher AL, Yokoyama S, et
al: Intronic miR-211 assumes the tumor suppressive function of its
host gene in melanoma. Mol Cell. 40:841–849. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Xia B, Yang S, Liu T and Lou G: miR-211
suppresses epithelial ovarian cancer proliferation and cell-cycle
progression by targeting Cyclin D1 and CDK6. Mol Cancer. 14:572015.
View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Ward A, Shukla K, Balwierz A, Soons Z,
König R, Sahin O and Wiemann S: MicroRNA-519a is a novel oncomir
conferring tamoxifen resistance by targeting a network of
tumour-suppressor genes in ER+ breast cancer. J Pathol.
233:368–379. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Kim TH, Kim YK, Kwon Y, Heo JH, Kang H,
Kim G and An HJ: Deregulation of miR-519a, 153, and 485-5p and its
clinicopathological relevance in ovarian epithelial tumours.
Histopathology. 57:734–743. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Hong L, Ya-Wei L, Hai W, Qiang Z, Jun-Jie
L, Huang A, Song-Tao Q and Yun-Tao L: MiR-519a functions as a tumor
suppressor in glioma by targeting the oncogenic STAT3 pathway. J
Neurooncol. 128:35–45. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Shao J, Cao J, Liu Y, Mei H, Zhang Y and
Xu W: MicroRNA-519a promotes proliferation and inhibits apoptosis
of hepatocellular carcinoma cells by targeting FOXF2. FEBS Open
Bio. 5:893–899. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Ge YZ, Xu LW, Xu Z, Wu R, Xin H, Zhu M, Lu
TZ, Geng LG, Liu H, Zhou CC, et al: Expression profiles and
clinical significance of microRNAs in papillary renal cell
carcinoma: A STROBE-compliant observational study. Medicine.
94:e7672015. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Zhou X, Zhu HQ, Ma CQ, Li HG, Liu FF,
Chang H and Lu J: MiR-1180 promoted the proliferation of
hepatocellular carcinoma cells by repressing TNIP2 expression.
Biomed Pharmacother. 79:315–320. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Chen PJ, Chen DS, Lai MY, Chang MH, Huang
GT, Yang PM, Sheu JC, Lee SC, Hsu HC and Sung JL: Clonal origin of
recurrent hepatocellular carcinomas. Gastroenterology. 96:527–529.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Cucchetti A, Piscaglia F, Caturelli E,
Benvegnù L, Vivarelli M, Ercolani G, Cescon M, Ravaioli M, Grazi
GL, Bolondi L, et al: Comparison of recurrence of hepatocellular
carcinoma after resection in patients with cirrhosis to its
occurrence in a surveilled cirrhotic population. Ann Surg Oncol.
16:413–422. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Okamoto M, Utsunomiya T, Wakiyama S,
Hashimoto M, Fukuzawa K, Ezaki T, Hanai T, Inoue H and Mori M:
Specific gene-expression profiles of non-cancerous liver tissue
predict the risk for multicentric occurrence of hepatocellular
carcinoma in hepatitis C virus-positive patients. Ann Surg Oncol.
13:947–954. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Hoshida Y, Villanueva A, Kobayashi M, Peix
J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, et
al: Gene expression in fixed tissues and outcome in hepatocellular
carcinoma. N Engl J Med. 359:1995–2004. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Utsunomiya T, Shimada M, Imura S, Morine
Y, Ikemoto T and Mori M: Molecular signatures of non-cancerous
liver tissue can predict the risk for late recurrence of
hepatocellular carcinoma. J Gastroenterol. 45:146–152. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Utsunomiya T, Ishikawa D, Asanoma M,
Yamada S, Iwahashi S, Kanamoto M, Arakawa Y, Ikemoto T, Morine Y,
Imura S, et al: Specific miRNA expression profiles of non-tumor
liver tissue predict a risk for recurrence of hepatocellular
carcinoma. Hepatol Res. 44:631–638. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Utsunomiya T, Shimada M, Morine Y, Tajima
A and Imoto I: Specific molecular signatures of non-tumor liver
tissue may predict a risk of hepatocarcinogenesis. Cancer Sci.
105:749–754. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Meckelein B, de Silva HA, Roses AD, Rao
PN, Pettenati MJ, Xu PT, Hodge R, Glucksman MJ and Abraham CR:
Human endopeptidase (THOP1) is localized on chromosome 19 within
the linkage region for the late-onset Alzheimer disease AD2 locus.
Genomics. 31:246–249. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Qi L, Li SH, Si LB, Lu M and Tian H:
Expression of THOP1 and its relationship to prognosis in non-small
cell lung cancer. PLoS One. 9:e1066652014. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Nomoto S, Hishida M, Inokawa Y, Takano N,
Kanda M, Nishikawa Y, Fujii T, Koike M, Sugimoto H and Kodera Y:
Expression analysis of THOP1 in background liver, a
prognostic predictive factor in hepatocellular carcinoma, extracted
by multiarray analysis. Ann Surg Oncol. 21:(Suppl 3). S443–S450.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Cressman DE, Diamond RH and Taub R: Rapid
activation of the Stat3 transcription complex in liver
regeneration. Hepatology. 21:1443–1449. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Calvisi DF, Ladu S, Gorden A, Farina M,
Conner EA, Lee JS, Factor VM and Thorgeirsson SS: Ubiquitous
activation of Ras and Jak/Stat pathways in human HCC.
Gastroenterology. 130:1117–1128. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Sonohara F, Nomoto S, Inokawa Y, Hishida
M, Takano N, Kanda M, Nishikawa Y, Fujii T, Koike M, Sugimoto H, et
al: High expression of Janus kinase 2 in background normal liver
tissue of resected hepatocellular carcinoma is associated with
worse prognosis. Oncol Rep. 33:767–773. 2015.PubMed/NCBI
|
